- Peptide (C)RRPNFQALSGNER,corresponding to amino acid residues 430-442 of rat kainate receptor GluK5 (Accession Q63273). Extracellular, N-terminus.
- Western blot analysis of rat hippocampus lysate (lanes 1 and 3) and rat brain lysate (lanes 2 and 4):1,2. Anti-GRIK5 (GluK5) (extracellular) Antibody (#AGC-042), (1:400).
3,4. Anti-GRIK5 (GluK5) (extracellular) Antibody, preincubated with GRIK5/GluK5 (extracellular) Blocking Peptide (#BLP-GC042).
- Expression of kainate receptor GluK5 in mouse hippocampusImmunohistochemical staining of perfusion-fixed frozen mouse brain sections using Anti-GRIK5 (GluK5) (extracellular) Antibody (#AGC-042), (1:300), followed by goat-anti-rabbit-Alexa-488. GluK5 staining (green) appears in neurons (horizontal arrows) of the pyramidal layer (Pyr) and in apical dendrites (vertical arrows) of mouse hippocampus. Nuclei are stained with DAPI (blue).
There are three glutamate receptor superfamilies defined by the specific agonist binding to them - NMDA, AMPA and kainate.
Several types of kainate receptors have been cloned and classified. Two of these have a high affinity to kainate (GLUK1 and GLUK2), while GLUK5, as well as other members of the family, have a lower affinity1. GLUK5, GLUK6 and GLUK7 have a 75-80% identical amino acid sequence making them a separate subfamily from the other kainate receptors.
The GLUK5 receptor, similar to its subfamily members, is a ligand-gated ion channel. It has an extracellular N-terminus comprised of eight glycosylation consensus sites, four transmembrane domains arranged in a three-plus-one pattern with a large intracellular domain between units three and four and a C-terminus2. GLUK5 is expressed in DRG neuron cell bodies where currents in these cells are preferentially induced by kainate and not AMPA3 and also in trigeminal neurons where kainate receptor antagonists are effective in a dural plasma protein extravasation model of migraine in rats4.
Little is known about the role of GLUK5 in pathologies. A study examining the role of the receptor in brain pathology using GLUK5 antagonists on hippocampal cells slices, found that blocking of the kainate receptor prevents the development of epileptic activity evoked by muscarinic antagonist. The administration of GLUK5 antagonists to conscious mice in the same study showed that the antagonist prevents limbic seizures induced by hippocampal pilocarpine perfusion without evident side effects. These findings suggest that GLUK5 antagonists may be effective in the treatment of epilepsy and further research in this field is required5.
Species reactivity key:
Alomone Labs is pleased to offer a highly specific antibody directed against an epitope of the rat kainate receptor GluK5. Anti-GRIK5 (GluK5) (extracellular) Antibody (#AGC-042) can be used in western blot, immunocytochemistry, and immunohistochemistry applications. The antibody recognizes an extracellular epitope and is thus ideal for detecting the receptor in living cells. It has been designed to recognize GluK5 from rat, human, and mouse samples.
- Human peripheral blood mononuclear cells (PBMCs) (1:300).
Bhandage, A.K. et al. (2017) J. Neuroimmunol. 305, 51.